Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 13/20 | 0.48 |
| ▸ | ANPEP | P15144 | 3/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977305 | 1.00 | RIPK1 (0.48) | RIPK1ANPEPROCK1 | |
| SCHEMBL1976309 | 1.00 | RIPK1 (0.48) | RIPK1ANPEPROCK1 | |
| Iodide SCHEMBL1975859 | 0.98 | RIPK1 (0.47) | RIPK1ANPEPROCK1 | |
| Hydrochloric Acid SCHEMBL1977306 | 0.98 | RIPK1 (0.47) | RIPK1ANPEP | |
| SCHEMBL24193618 | 0.82 | RIPK1 (0.48) | RIPK1 | |
| SCHEMBL23408379 | 0.78 | RIPK1 (0.46) | RIPK1 | |
| SCHEMBL23447189 | 0.78 | RIPK1 (0.46) | RIPK1ROCK1 | |
| SCHEMBL19228597 | 0.77 | RIPK1 (0.40) | RIPK1ROCK1 | |
| SCHEMBL19207819 | 0.76 | RIPK1 (0.66) | RIPK1 | |
| SCHEMBL28695677 | 0.76 | RIPK1 (0.50) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994191-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994190-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-114437105-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| CN-114437105-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-109071504-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-03-08 | — | — | CN | disclosed |
| US-20200317691-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2019-04-18 | — | — | US | disclosed |
| EP-3414239-A2 | INHIBITORS OF RECEPTOR-INTERACTING PROTEIN KINASE 1 | Denali Therapeutics Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-04-12 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
| EP-2509981-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | LILLY CO ELI (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8299061-B2 | Inhibitors of diacylglycerol acyltransferase | ELI LILLY AND COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2509981-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Eli Lilly and Company (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110144091-A1 | Inhibitors of Diacylglycerol Acyltransferase | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2011071840-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885ANPEP 4183/4885ROCK1 318/4885 |
| US-20200317691-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885ANPEP 4183/4885ROCK1 318/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885ANPEP 4183/4885ROCK1 318/4885 |
| US-20110144091-A1 | Inhibitors of Diacylglycerol Acyltransferase | DGAT1, DGAT2, LCAT | RIPK1 3703/4885ANPEP 985/4885ROCK1 734/4885 |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885ANPEP 4183/4885ROCK1 318/4885 |
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885ANPEP 4183/4885ROCK1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.